Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"

Nalee Kim; Jinsil Seong

doi:10.1016/j.jhep.2020.04.016

YUHSpace

BROWSE

0 388

Cited 0 times in

Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"

Authors: Nalee Kim ; Jinsil Seong

Citation: JOURNAL OF HEPATOLOGY, Vol.73(2) : 468-469, 2020-08

Journal Title: JOURNAL OF HEPATOLOGY

ISSN: 0168-8278

Issue Date: 2020-08

MeSH: Carcinoma, Hepatocellular* / surgery ; Humans ; Liver Neoplasms* / surgery ; Radiofrequency Ablation* ; Radiosurgery* ; Sorafenib

Full Text: https://www.sciencedirect.com/science/article/pii/S0168827820302294

DOI: 10.1016/j.jhep.2020.04.016

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

Yonsei Authors: Kim, Nalee(김나리) https://orcid.org/0000-0003-4742-2772
Seong, Jin Sil(성진실) https://orcid.org/0000-0003-1794-5951

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/190039

사서에게 알리기

Show full item record Find it @ YMLIB

YUHSpace: Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"

YUHSpace

BROWSE

Browse

Links